Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price lifted by JPMorgan Chase & Co. from $78.00 to $79.00 in a research note published on Wednesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock. A number of other brokerages also recently issued reports on APLS. Robert W. […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.73) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.73), Briefing.com reports. The business had revenue of $146.38 million during the quarter, compared to the consensus estimate of $143.34 million. Apellis Pharmaceuticals had a negative return […]
Covestor Ltd raised its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 564.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 797 shares of the company’s stock after purchasing an additional 677 shares during the period. Covestor Ltd’s holdings in Apellis […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $92.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 42.97% from the company’s current price. Several […]